Open AccessPrevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)
Author(s) -
Erin A. Bohula,
Stephen D. Wiviott,
Robert P. Giugliano,
Michael A. Blazing,
JeongGun Park,
Sabina A. Murphy,
Jennifer A. White,
François Mach,
Frans Van de Werf,
Anthony J. Dalby,
Harvey D. White,
Andrew M. Tershakovec,
Christopher P. Can,
Eugene Braunwald
Publication year - 2017
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.117.029095
Subject(s) - medicine , ezetimibe , stroke (engine) , acute coronary syndrome , simvastatin , hazard ratio , myocardial infarction , population , cardiology , atrial fibrillation , placebo , statin , confidence interval , environmental health , engineering , mechanical engineering , alternative medicine , pathology
Patients who experience an acute coronary syndrome are at heightened risk of recurrent ischemic events, including stroke. Ezetimibe improved cardiovascular outcomes when added to statin therapy in patients stabilized after acute coronary syndrome. We investigated the efficacy of the addition of ezetimibe to simvastatin for the prevention of stroke and other adverse cardiovascular events in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial), with a focus on patients with a stroke before randomization.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom